Obstructive Sleep Apnea – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Obstructive Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions.
Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while driving fatigue and reduced productivity. Moreover, OSA poses risks to driving safety, as drowsiness from poor sleep can lead to accidents, emphasizing the need for early diagnosis and effective management.
The Obstructive Sleep Apnea drugs in development market research report provide comprehensive information on the therapeutics under development for Obstructive Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Obstructive Sleep Apnea | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Obstructive Sleep Apnea therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Obstructive Sleep Apnea pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Obstructive Sleep Apnea treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aceragen IncApnimed Inc
Bayer AG
Bioprojet SCR
Brigham and Women's Hospital
Citrine (Shanghai) Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Evero Health Ltd
Idorsia Pharmaceutical Ltd
IGNIS Therapeutics Shanghai Co Ltd
Incannex Healthcare Ltd
Merck & Co Inc
Monash University
Mosanna Therapeutics AG
ResolutionRx Ltd
Shionogi-Apnimed Sleep Science LLC
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Obstructive Sleep Apnea reports